Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Bile Duct Neoplasms × MK 2206 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioma 1 Gallbladder Neoplasms 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Bile Duct Neoplasms 1

Interventions

galactomannan 1 Phototherapy 1 Photochemotherapy 1 Pharmacogenomic Testing 1 MK 2206 1 Laser Therapy 1 Fluorouracil 1 Electroporation 1 Dihematoporphyrin Ether 1 Chemotherapy, Adjuvant 1 AZD 6244 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01859182 2014-09-09

Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 2 Withdrawn

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡